Screening for blunt cerebrovascular injuries is cost-effective

Deborah Kaye, Karen Brasel, Todd Neideen, John A. Weigelt

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Screening for blunt carotid and vertebral injury (BCVI) is increasing without a clear understanding of whether the chosen screening approach is cost-effective. We hypothesized that screening for BCVI using computed tomography angiography (CTA) was cost-effective in populations at high risk for BCVI. Methods: A decision analysis was performed modeling current BCVI screening approaches: no screening, duplex ultrasound, magnetic resonance angiography, angiography, and CTA. Treatment options included antiplatelet therapy, anticoagulation, stents for pseudoaneurysm, and no treatment. Probability estimates for incidence of injury and stroke, sensitivity and specificity of the screening modality, and type of treatment were taken from published data. Average wholesale price and medicare reimbursement costs were used. Two populations were analyzed; high-risk and overall blunt trauma populations. Two perspectives were taken; societal (including lifetime stroke costs) and institutional (ignoring lifetime stroke costs). Results: In the high-risk population, from a societal perspective, CTA has the lowest cost and stroke rate; $3,727 per patient screened with a 1% stroke rate. No treatment has the highest cost and stroke rate. From an institutional perspective, no screening is the least costly option but has an 11% stroke rate. Duplex ultrasound is the most cost-effective screening modality; $8,940 per stroke prevented. Conclusion: From the societal perspective, CTA is the most cost-effective screening strategy for patients at high risk for BCVI. From an institutional perspective, CTA prevents the most strokes at a reasonable cost.

Original languageEnglish (US)
Pages (from-to)1051-1056
Number of pages6
JournalJournal of Trauma - Injury, Infection and Critical Care
Volume70
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Nonpenetrating Wounds
Costs and Cost Analysis
Stroke
Wounds and Injuries
Population
Therapeutics
Decision Support Techniques
Magnetic Resonance Angiography
False Aneurysm
Medicare
Stents
Angiography
Computed Tomography Angiography
Sensitivity and Specificity

Keywords

  • Carotid injury
  • Cost-effectiveness
  • Decision analysis

ASJC Scopus subject areas

  • Surgery
  • Critical Care and Intensive Care Medicine

Cite this

Screening for blunt cerebrovascular injuries is cost-effective. / Kaye, Deborah; Brasel, Karen; Neideen, Todd; Weigelt, John A.

In: Journal of Trauma - Injury, Infection and Critical Care, Vol. 70, No. 5, 05.2011, p. 1051-1056.

Research output: Contribution to journalArticle

Kaye, Deborah ; Brasel, Karen ; Neideen, Todd ; Weigelt, John A. / Screening for blunt cerebrovascular injuries is cost-effective. In: Journal of Trauma - Injury, Infection and Critical Care. 2011 ; Vol. 70, No. 5. pp. 1051-1056.
@article{b29302fa92574e36a88070ec99baf56a,
title = "Screening for blunt cerebrovascular injuries is cost-effective",
abstract = "Background: Screening for blunt carotid and vertebral injury (BCVI) is increasing without a clear understanding of whether the chosen screening approach is cost-effective. We hypothesized that screening for BCVI using computed tomography angiography (CTA) was cost-effective in populations at high risk for BCVI. Methods: A decision analysis was performed modeling current BCVI screening approaches: no screening, duplex ultrasound, magnetic resonance angiography, angiography, and CTA. Treatment options included antiplatelet therapy, anticoagulation, stents for pseudoaneurysm, and no treatment. Probability estimates for incidence of injury and stroke, sensitivity and specificity of the screening modality, and type of treatment were taken from published data. Average wholesale price and medicare reimbursement costs were used. Two populations were analyzed; high-risk and overall blunt trauma populations. Two perspectives were taken; societal (including lifetime stroke costs) and institutional (ignoring lifetime stroke costs). Results: In the high-risk population, from a societal perspective, CTA has the lowest cost and stroke rate; $3,727 per patient screened with a 1{\%} stroke rate. No treatment has the highest cost and stroke rate. From an institutional perspective, no screening is the least costly option but has an 11{\%} stroke rate. Duplex ultrasound is the most cost-effective screening modality; $8,940 per stroke prevented. Conclusion: From the societal perspective, CTA is the most cost-effective screening strategy for patients at high risk for BCVI. From an institutional perspective, CTA prevents the most strokes at a reasonable cost.",
keywords = "Carotid injury, Cost-effectiveness, Decision analysis",
author = "Deborah Kaye and Karen Brasel and Todd Neideen and Weigelt, {John A.}",
year = "2011",
month = "5",
doi = "10.1097/TA.0b013e318211857d",
language = "English (US)",
volume = "70",
pages = "1051--1056",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Screening for blunt cerebrovascular injuries is cost-effective

AU - Kaye, Deborah

AU - Brasel, Karen

AU - Neideen, Todd

AU - Weigelt, John A.

PY - 2011/5

Y1 - 2011/5

N2 - Background: Screening for blunt carotid and vertebral injury (BCVI) is increasing without a clear understanding of whether the chosen screening approach is cost-effective. We hypothesized that screening for BCVI using computed tomography angiography (CTA) was cost-effective in populations at high risk for BCVI. Methods: A decision analysis was performed modeling current BCVI screening approaches: no screening, duplex ultrasound, magnetic resonance angiography, angiography, and CTA. Treatment options included antiplatelet therapy, anticoagulation, stents for pseudoaneurysm, and no treatment. Probability estimates for incidence of injury and stroke, sensitivity and specificity of the screening modality, and type of treatment were taken from published data. Average wholesale price and medicare reimbursement costs were used. Two populations were analyzed; high-risk and overall blunt trauma populations. Two perspectives were taken; societal (including lifetime stroke costs) and institutional (ignoring lifetime stroke costs). Results: In the high-risk population, from a societal perspective, CTA has the lowest cost and stroke rate; $3,727 per patient screened with a 1% stroke rate. No treatment has the highest cost and stroke rate. From an institutional perspective, no screening is the least costly option but has an 11% stroke rate. Duplex ultrasound is the most cost-effective screening modality; $8,940 per stroke prevented. Conclusion: From the societal perspective, CTA is the most cost-effective screening strategy for patients at high risk for BCVI. From an institutional perspective, CTA prevents the most strokes at a reasonable cost.

AB - Background: Screening for blunt carotid and vertebral injury (BCVI) is increasing without a clear understanding of whether the chosen screening approach is cost-effective. We hypothesized that screening for BCVI using computed tomography angiography (CTA) was cost-effective in populations at high risk for BCVI. Methods: A decision analysis was performed modeling current BCVI screening approaches: no screening, duplex ultrasound, magnetic resonance angiography, angiography, and CTA. Treatment options included antiplatelet therapy, anticoagulation, stents for pseudoaneurysm, and no treatment. Probability estimates for incidence of injury and stroke, sensitivity and specificity of the screening modality, and type of treatment were taken from published data. Average wholesale price and medicare reimbursement costs were used. Two populations were analyzed; high-risk and overall blunt trauma populations. Two perspectives were taken; societal (including lifetime stroke costs) and institutional (ignoring lifetime stroke costs). Results: In the high-risk population, from a societal perspective, CTA has the lowest cost and stroke rate; $3,727 per patient screened with a 1% stroke rate. No treatment has the highest cost and stroke rate. From an institutional perspective, no screening is the least costly option but has an 11% stroke rate. Duplex ultrasound is the most cost-effective screening modality; $8,940 per stroke prevented. Conclusion: From the societal perspective, CTA is the most cost-effective screening strategy for patients at high risk for BCVI. From an institutional perspective, CTA prevents the most strokes at a reasonable cost.

KW - Carotid injury

KW - Cost-effectiveness

KW - Decision analysis

UR - http://www.scopus.com/inward/record.url?scp=79955769088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955769088&partnerID=8YFLogxK

U2 - 10.1097/TA.0b013e318211857d

DO - 10.1097/TA.0b013e318211857d

M3 - Article

VL - 70

SP - 1051

EP - 1056

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 5

ER -